Format

Send to

Choose Destination
Pediatr Blood Cancer. 2015 Nov;62(11):1956-61. doi: 10.1002/pbc.25608. Epub 2015 Jul 14.

Survival among children and adults with sickle cell disease in Belgium: Benefit from hydroxyurea treatment.

Author information

1
Hemato-Oncology Unit, Hôpital Universitaire des Enfants Reine Fabiola, U.L.B., Brussels, Belgium.
2
Department of Clinical Chemistry, Hôpital Erasme, U.L.B., Brussels, Belgium.
3
Hemato-Oncology Unit, Cliniques Universitaires Saint Luc, Brussels, Belgium.
4
Department of Pediatrics, Hôpital Saint-Pierre, U.L.B., Brussels, Belgium.
5
Department of Pediatrics, Hôpital de Jolimont, La Louvière, Belgium.
6
Hemato-Oncology Unit, Hôpital Universitaire Brugmann, U.L.B., Brussels, Belgium.
7
Hemato-Oncology Unit, Hôpital Régional de la Citadelle, ULg, Liège, Belgium.
8
Laboratory of Hematology, CHU-Brugmann, Hôpital Universitaire des Enfants Reine Fabiola, U.L.B., Brussels, Belgium.
9
Hemato-Oncology Unit, Hôpital Erasme, U.L.B., Brussels, Belgium.

Abstract

OBJECTIVE:

To evaluate the survival of patients with sickle cell disease (SCD) recorded in the Belgian SCD Registry and to assess the impact of disease-modifying treatments (DMT).

METHOD:

The Registry created in 2008 included patients of eight centers. All available data in 2008 were retrospectively encoded in the database. After 2008 and until 2012, all data were recorded prospectively for already registered patients as well as newly diagnosed subjects. Data were registered from neonatal screening or from diagnosis (first contact) until last follow-up or death. Data included diagnosis, demography, and outcome data.

RESULTS:

We collected data from 469 patients over a 5,110 patient years (PY) follow-up period. The global mortality rate was low (0.25/100 PY), although 13 patients died (2.8%) and was similar between children, adolescents (10-18 years), and young adults (P = 0.76). Out of the cohort, 185 patients received hydroxyurea at last follow-up (median duration of treatment: 10.3 years), 90 underwent hematopoietic stem cell transplantation (HSCT), 24 were chronically transfused, and 170 had never had any DMT. Hydroxyurea showed significant benefit on patients outcome as reflected by a lower mortality rate compared to transplanted individuals or people without DMT (0.14, 0.36, and 0.38 per 100 PY, respectively) and by higher Kaplan-Meier estimates of 15 year survival (99.4%) compared to HSCT (93.8%; P = 0.01) or no DMT groups (95.4%; P = 0.04).

CONCLUSION:

SCD mortality in Belgium is low with no increase observed in young adults. Patients treated with hydroxyurea demonstrate a significant benefit in survival when compared to those without DMT or transplanted.

KEYWORDS:

hydroxyurea; mortality; sickle cell disease; survival

Comment in

PMID:
26173735
DOI:
10.1002/pbc.25608
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley Icon for ORBi (University of Liege)
Loading ...
Support Center